Brief: HBM Holdings Saus Unit And Boostimmune Entered Agreement
27/02/2024 24:49
Feb 27 (Reuters) - Hbm Holdings Ltd 2142.HK :
* UNIT AND BOOSTIMMUNE, INC ENTERED INTO AN ANTIBODY-DRUG
CONJUGATE DISCOVERY COLLABORATION AGREEMENT
* AGREEMENT AS A STRATEGIC PARTNERSHIP TO DEVELOP ADC
THERAPY
* UNIT TO PROVIDE 2 LIGHT & 2 HEAVY CHAIN HARBOUR MICE
PLATFORM
FOR BOOSTIMMUNE TO DEVELOP ADC THERAPIES AGAINST NOVEL TARGETS
Source text for Eikon: ID:n11076680-1
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study